J&J Unit Veridex to Help Nuvera Market Its Cancer Dxs Worldwide

Terms of the deal call for Veridex to market the tests, which were developed on the Affymetrix GeneChip platform to predict response to tamoxifen and taxane-containing chemotherapy in breast cancer. The deal is open to other tests in as-yet unknown indications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.